Articles tagged with Cancer Immunotherapy
Researchers at the University of Turku have developed a reliable laboratory model to study BAP1-deficient melanomas, which are resistant to immunotherapies. The new tool could lead to novel immunotherapy combinations for aggressive melanomas.
Researchers developed genetically engineered CAR T cells specifically targeting bladder cancer cells and delivered them directly to the bladder via a catheter. This approach shows promise in controlling bladder tumors in mice and may be effective in humans, offering an alternative to life-altering procedures like bladder removal.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
Researchers identified a critical biological difference in glioblastoma development between male and female laboratory models, pinpointing an immune pathway fueled by GABA in females. Blocking this signal improves outcomes in women, but not men.
Researchers will develop genetic boosters and "two-factor authentication" for CAR T cell therapy, targeting HER2-positive lung, breast, and colon tumors. The project aims to improve the efficacy of CAR T cells against solid tumors while reducing collateral damage.
Dr. Nowicki's research aims to develop a next-generation CAR-T cell therapy targeting GD2, a protein found on osteosarcoma cells, with enhanced immune-signaling molecule TNF-alpha. The grant will support preclinical studies to evaluate safety and effectiveness in laboratory and animal models.
The FDA has accepted Genentech's supplemental Biologic License Application for atezolizumab, supported by phase III ATOMIC trial results. The trial showed a 50% reduction in cancer recurrence or death and 86.3% disease-free survival rate.
Research reveals B7x facilitates immune evasion by creating a highly immunosuppressive tumor microenvironment, leading to accelerated tumor growth rates and worsened survival outcomes. Combinatorial immunotherapy targeting B7x and PD-1/PD-L1 or CTLA-4 improves antitumor responses.
Researchers at UMass Amherst have designed a new therapy that combines engineered Salmonella bacteria with oncolytic viruses to target liver and pancreatic cancer. The treatment showed promising results in animal models, leading to significant tumor reduction and improved survival rates.
Researchers at Max Delbrück Center have found a way to improve CAR-T cancer therapy by engineering cells to express the receptor CCR7. This allows CAR-T cells to penetrate lymph nodes more efficiently and kill cancer cells quickly.
Researchers used magnetic particle imaging to track cell therapy injections in mice, finding that it can visualize therapeutic cells as they inject them. The technique shows promise for developing more effective treatments for certain cancers, autoimmune diseases like MS, and neurological conditions.
Researchers identified microRNA-25 as a key player in creating an immune-suppressive tumor environment that resists cancer immunotherapy. Removing miR-25 reshaped the environment and activated anti-tumor immune responses, suggesting a potential target for converting 'cold' tumors into responsive 'hot' tumors.
In a landmark international trial, teclistamab outperformed standard treatments in extending survival and remission for patients with relapsed multiple myeloma. Nearly 70% of patients remained disease-free after 18 months, and nearly two-thirds achieved complete remission.
A Dartmouth Cancer Center study reveals that the location of immune cells within a tumor can determine whether they aid or hinder the anti-cancer response. Macrophages, often seen as helpful in clearing debris, have been found to play complex roles depending on their location and signals produced.
A phase I clinical trial is testing whether a tumor-targeting virus can help immunotherapy work more effectively against aggressive neuroendocrine tumors. The study uses a combination of immunotherapy medications and an oncolytic virus delivered directly into the tumors, aiming to improve treatment outcomes.
Researchers from The University of Osaka discovered that only a small proportion of CD8 T cells undergo sustained clonal expansion in multiple myeloma immunotherapy, leading to the strongest anti-tumor response. Early immune activity could help predict which cells will become effective cancer fighters.
A new cytokine-armored CAR-T cell therapy has been developed to attack aggressive brain tumors in mice while reducing side effects. The approach recruits the body's immune system using IL-12 and DR-18 proteins, strengthening the anti-cancer response and improving tumor control.
Researchers discovered a new gene expression signature linked to prolonged overall survival in patients with metastatic castration-resistant prostate cancer who responded to combined immune checkpoint inhibitors. The biomarker has the potential to help identify patients most likely to benefit from this treatment combination.
Researchers at the Francis Crick Institute have developed a new method to enhance anti-cancer immunity by redirecting non-specialized immune cells to present a broader range of tumor antigens. This approach, leveraging understanding of dendritic cell biology, has shown promise in reducing tumour growth and amplifying responses in mice.
The LUNA-2 trial will pair immunotherapy with fecal microbiota transplantation (FMT) to boost treatment effectiveness in people with non-small cell lung cancer. If successful, it could provide new treatment options for those living with the disease, helping them live longer and with fewer side effects.
Researchers found that a common asthma drug can help fight aggressive cancers by blocking the CysLTR1 molecule. The study used mouse models and human tissue samples to demonstrate its potential in treating triple-negative breast cancer and other tough tumors.
A new mRNA-based strategy amplifies the T-cell response to vaccines, enabling more powerful cancer vaccines and stronger protection against infectious diseases. The approach reprograms immune cells from within using mRNA instructions that expand cancer-fighting T cells.
The Alliance A082402 study evaluates the effectiveness of involved-station I²-PORT in reducing NSCLC recurrence without long-term side effects. Participants will undergo randomized treatment with or without targeted radiation therapy after surgery.
Researchers review how engineered nanomaterials can be used to deliver antigens, improve antigen presentation, support T cell priming and infiltration, and reshape tumor niches. The materials are designed to intervene across the cancer-immunity cycle, improving immune activation while reducing off-target effects.
A recent study reveals that combining iNKT cell therapy with antigen-presenting cells activated by a lipid compound triggers effective antitumor immunity. The therapy generates memory-phenotype T cells that can recognize and respond to specific threats, offering a promising personalized approach to cancer treatment.
Researchers developed a blood test that identifies nine cellular neighborhoods surrounding tumors, correlating with tumor response to immunotherapy and patient prognosis. The test provides real-time access to information about successful therapies.
Dr. Aparna Bhaduri receives $750k Pershing Square Sohn Cancer Prize for her innovative glioblastoma research. Her advanced human organoid models reveal how tumors interact with the immune system and brain cells, driving tumor aggressiveness.
Researchers have discovered a biomarker for chemotherapy resistance in small cell lung cancer, which can help identify cells that become more invasive and lead to treatment resistance. Targeting these cells with YAP1 may be a possible strategy to improve patient outcomes.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
A study published in Cell Reports Medicine found that inhibiting RNase H2 can cause significant damage to DNA and activate the innate immune system to produce signals that attract T cells to attack the tumor. This approach could lead to improved patient outcomes for patients with triple-negative breast cancer.
Binghamton University Professor L. Nathan Tumey is working on developing new chemical technologies for antibody-drug-conjugates to push the boundaries of what can be accomplished in ADCs. The goal is to awaken tumor-associated immune cells and prevent cancer regrowth.
A research team at the University of Cologne discovered that the protein cFLIP can be used to override the defences of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. Targeting cFLIP could re-activate cell death in lymphoma cells and provide a new therapy option.
A Mayo Clinic study provides preclinical evidence for a targeted approach to managing immune-related kidney inflammation triggered by immunotherapy. The findings suggest that TNF-alpha blockade may improve markers of kidney injury and could be explored as a preventive measure.
Researchers found that tumor genetics alone did not explain which patients responded to combination therapy, but rather the tumor's immune environment. Patients with active networks of cancer-killing T cells were more likely to benefit from treatment, while those with dense clusters of plasma cells were less likely.
A new treatment using low-dose nivolumab injections into precancerous oral lesions significantly reduced lesion size and risk of cancer progression. The study showed a 60% average reduction in lesion size and complete pathologic response in six patients, with no dose-limiting side effects.
A new study reveals that patients with stage two or three bowel cancer who received immunotherapy before surgery have remained cancer-free for over three years. The trial found that this treatment approach can provide more durable cancer control compared to traditional post-op chemotherapy.
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
Chemokines regulate immune cell infiltration and local immunity in tumors, and targeting their receptor axis has emerged as a promising therapeutic target in cancer immunotherapy. Chemokine-modulating strategies combining with other immunotherapies have demonstrated considerable synergistic potential.
The hospital is conducting a phase 2 clinical trial evaluating STAR0602, which activates the immune system to stop tumor growth across various cancers. The goal of this study is to identify safer and more effective treatments for people with advanced cancers.
The UTHealth Houston-developed dual-payload antibody-drug conjugate technology has been acquired by Eli Lilly, marking a major step towards clinical translation. This technology delivers chemotherapy directly to tumor cells while minimizing damage to healthy tissue, offering a promising approach to cancer treatment.
Researchers from UT MD Anderson Cancer Center present studies on single-cell technologies, integrative computational approaches, and experimental therapeutics, highlighting innovations in mRNA vaccines and spatial multi-omics techniques. The studies aim to improve immunotherapy responses and detect treatment-resistant glioma cells.
Researchers from Penn Medicine will showcase progress in CAR T cell therapies for solid tumors, as well as a multi-chain CAR T cell therapy for ovarian cancer. The presentation also highlights a new strategy targeting pancreatic cancer before it forms and at-home cervical cancer testing.
A University of Calgary-led study found that multiple myeloma tumour cells adapt in multiple ways to become resistant to treatment, highlighting the need for personalized cancer therapy. The research aims to develop next-generation treatments designed to anticipate and overcome these changes.
Dr. Kenneth M. Murphy is being recognized for his groundbreaking research on dendritic cell subsets, which regulate adaptive immune responses and have advanced the understanding of antigen presentation and immune system regulation. His work has informed strategies to enhance antitumor immunity and cancer immunotherapy.
Researchers have developed a new single-cell technology called CIPHER-seq that captures the timing of cytokine activity with greater accuracy. This allows for a clearer view of immune cell behavior and strengthens the foundation for understanding cancer, inflammation, and treatment resistance.
Researchers have identified a natural compound called PGG as a MAT2A inhibitor that promotes protein degradation while inhibiting enzymatic activity, offering a promising new strategy for cancer immunotherapy.
Researchers have developed a new CAR T therapy that targets tumor-supporting cells in pancreatic cancer, paving the way for a potentially safer and more effective treatment. The therapy uses lipid nanoparticles to deliver CAR instructions directly to patient T cells, resulting in higher expression rates and improved efficacy compared t...
Researchers found that combining targeted radiation therapy with BO-112 and anti-PD-1 therapy before surgery activated the immune system to fight cancer. This approach reshaped the tumor microenvironment to support T-cell activity, resulting in fewer cancer cells and a more effective anti-tumor response.
Researchers have developed microfluidic platforms that capture dynamic cell behavior and reveal how cancers evade immunity, how therapies succeed or fail. These systems can test cellular therapies, identify biomarkers, and support personalized cancer treatment.
Gladstone Institutes has secured over 105,000 square feet of future laboratory space in a newly constructed building, empowering its scientists to create medicines of the future. The new space will be home to approximately 300 scientists across 20 labs, equipped with state-of-the-art equipment and computational abilities.
A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.
Researchers at Cold Spring Harbor Laboratory found that antibodies produced in response to cancer can attack the brain, causing autoimmune diseases like lupus and multiple sclerosis. The study suggests that these antibodies may be harnessed to develop new treatments for triple-negative breast cancer.
Researchers equipped immune cells with proteins to recognize cancer cell metabolism, enhancing their ability to infiltrate and control tumor growth. The new therapy approach shows promise in treating solid tumors, overcoming a key limitation of existing immunotherapies.
Researchers engineered supercharged T cells that can recognize and kill prostate cancer cells more effectively. By fine-tuning how they physically interact with tumor cells, the T cells form a stronger bond, allowing them to deliver a targeted immune response without damaging healthy tissue.
Researchers at the University of Pennsylvania developed lipid nanoparticles that modify immune metabolism to strengthen mRNA vaccines and reduce common side effects. The new lipid boosts the metabolism of immune cells, providing energy for the body's defenses while dialing down inflammatory signals.
Researchers at UCLA have developed a novel immunotherapy that uses CAR-NKT cell therapy to fight endometrial cancer. The therapy achieved complete tumor elimination and prolonged survival in mouse models, outperforming conventional CAR-T cell therapies.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...